Related Experiment Video
Updated: Jun 17, 2026
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer
Chang Qi1,2, Yalun Li1,2, Hao Zeng1,2
1Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Abstract:
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths and represents a substantial disease burden worldwide. Immune checkpoint inhibitors combined with chemotherapy are the standard first-line therapy for advanced NSCLC without driver mutations. Programmed death-ligand 1 (PD-L1) is currently the only approved immunotherapy marker. PD-L1 detection methods are diverse and have developed rapidly in recent years, such as improved immunohistochemical detection methods, the application of liquid biopsy in PD-L1 detection, genetic testing, radionuclide imaging, and the use of machine learning methods to construct PD-L1 prediction models. This review focuses on the detection methods and challenges of PD-L1 from different sources, and discusses the influencing factors of PD-L1 detection and the value of combined biomarkers. Provide support for clinical screening of immunotherapy-advantage groups and formulation of personalized treatment decisions.
Insights
This review explores advanced methods for detecting Programmed Death-Ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC). It aims to improve patient selection for immunotherapy by analyzing diverse detection techniques and biomarkers.
Area of Science:
- Oncology
- Immunology
- Medical Diagnostics
Background:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality globally.
- Immune checkpoint inhibitors plus chemotherapy are standard first-line treatment for advanced NSCLC without driver mutations.
- Programmed Death-Ligand 1 (PD-L1) is the sole approved biomarker for immunotherapy efficacy.
Purpose of the Study:
- To review and analyze diverse methods for detecting PD-L1 expression in NSCLC.
- To discuss challenges, influencing factors, and the value of combined biomarkers in PD-L1 detection.
- To support clinical screening for immunotherapy-responsive patients and personalized treatment strategies.
Main Methods:
- Review of current literature on PD-L1 detection methodologies.
- Analysis of immunohistochemistry, liquid biopsy, genetic testing, and radionuclide imaging.
- Exploration of machine learning models for PD-L1 prediction.
Main Results:
- PD-L1 detection methods are rapidly evolving, offering diverse approaches.
- Various factors influence PD-L1 detection accuracy and reliability.
- Combined biomarkers show potential for enhanced predictive value.
Conclusions:
- Accurate PD-L1 detection is crucial for optimizing immunotherapy in NSCLC.
- Emerging technologies offer promising avenues for improved diagnostic accuracy.
- Personalized treatment decisions can be enhanced through comprehensive biomarker analysis.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
